








Why Publish with ASPET?

ASPET journals provide leading primary research and review articles to scientists in pharmacology and related fields



Rapid Publication

Accepted manuscripts in *DMD*, *JPET*, and *MolPharmacol* are posted online within 1-3 business days as Fast Forward articles. Fast Forward articles are indexed by PubMed and are citable. All ASPET journals publish continuously – the copyedited and formatted version of all articles go online as they are ready.

Low Page Charges & Free Color Illustrations

\$90 per page but only \$50 per page for ASPET members – the savings from one article outweigh the cost of membership. ASPET does not charge a fee for color figures.

Alerting Services

Emailed alerts for Fast Forward articles and complete-issue tables of contents, multiple RSS feeds, and social media updates inform researchers of new content as soon as it goes online. All articles are featured on Facebook and Twitter.

Wide Dissemination

Fast Forward articles are freely accessible immediately and remain free accessible after the formatted version is posted. All formatted content is freely accessible during a five-year rolling window. Low subscription prices keep ASPET journals affordable to libraries.

Optimized Discoverability

ASPET's journals are covered by abstracting and indexing services used around the world. Journal metadata is provided to A&I services and Google for faster inclusion.

Funder Compliance

NIH-funded articles are deposited by ASPET with PubMed Central on behalf of authors. ASPET's journals are Plan S compliant: Plan S-funded authors may deposit the manuscript version of their articles in an open repository under a CC BY license.

Open Access


Authors may opt to publish under either a CC BY or CC BY-NC license. Authors retain copyright and may post, deposit, and share their open access articles as they wish. All *PR&P* articles are open access.

Direct Submission from bioRxiv

Manuscripts posted to the bioRxiv preprint server can be transferred easily to the manuscript submission system for *DMD*, *JPET*, and *MolPharmacol*.

Journal of Pharmacology and Experimental Therapeutics

jpet.aspetjournals.org



A leading research journal in the field of pharmacology, the *Journal of Pharmacology and Experimental Therapeutics (JPET)* provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.

Scope:

JPET invites for review original papers dealing with the interactions of chemicals with biological systems. All aspects of pharmacology and therapeutics are within the scope of *JPET*. Research papers should provide rigorous quantitative analyses and/or new insights on pharmacological mechanisms. All manuscripts are initially screened by the Editorial Board to ensure that each manuscript meets the above criteria before peer review. Manuscripts that provide descriptive case reports, lack complete dose-response determinations, or do not communicate novel findings are not acceptable and will be rejected without peer review. Manuscripts dealing primarily with new methods will be reviewed only if data are presented showing that new or more reliable pharmacological information has been obtained with their use.

JPET also invites authors to submit minireviews (4,000 – 6,000 words) that provide concise perspectives, overviews, or commentaries of contemporary or emerging topics in pharmacology.

- Published continuously
- Impact Factor: 3.561 (2019)
- H Index: 209
- Acceptance rate: 42%
- Average time to first decision: 20 days
- Average time to acceptance: 89 days
- Manuscripts published online within 2-3 business days of acceptance and freely accessible to all

Editorial Board

Kenneth D. Tew, *Editor*
Joe Blumer, *Minireviews Editor*

Associate Editors:

Michael Frohman
James Gallo
Yuichi Hattori
John Hayes
Lawrence H. Lash
Roberto Levi
Gary O. Rankin
Kent Vrana
Raymond J. Winquist
Susan K. Wood

Editorial Advisory Board:

Geoffrey W. Abbott
Thomas J. Abbruscato
François Alhenc-Gelas
Bradley T. Andresen
Thomas M. Argentieri
John Auchampach
Jack Bergman
Andrea Cignarella
Gregory T. Collins
Mark J. Crabtree
Ann Daly
Piyali Dasgupta
Annarita Di Lorenzo
Frederick J. Ehler
Steven J. Feinmark
Stephen F. Flaim
Hiroyuki Fukui
Eric R. Gross
Paul Heerdt
James K. Hennen
Edwin K. Jackson
Emily M. Jutkiewicz
Mark R. Kelley
Lewis B. Kinter
M.N.V. Ravi Kumar
Giorgio Minotti
Mahmood S. Mozaffari
Jamal S. Mustafa
Michael A. Nader
Nazareno Paolucci
Andreas Papapetropoulos
D. Samba Reddy
Gaetano Santulli
Roger D. Speakman
David A. Taylor
Sandra P. Welch
Jack Yalowich
Bryan K. Yamamoto



facebook.com/jpetaspetjournal

twitter.com/JPET_Journal



Editorial Board

Kathryn E. Meier, *Editor*

John Tesmer, *Deputy Editor*

Associate Editors:

Cecilia Bouzat
Raymond Evers
John Hepler
Sridhar Mani
Andrew Morris
Jeanne Nerbonne
Manojkumar Puthenveedu
Alan Smrcka

Minireview Editor:

Martin Michel

Statistics Editors:

Martin Michel
Harvey J. Motulsky
T.J. Murphy

Emerging Concepts Editor:


David Gwartz

Editorial And Advisory Board:

Katerina Akassoglou
Giuseppe Battaglia
Jeffrey L. Benovic
Nigel J.M. Birdsall
Mary-Ann Bjornsti
Laura Bohn
Wendy Bollag
Joan Heller Brown
Moritz Bunemann
Thomas Burris
Meritxell Canals
William A. Catterall
Niels Decher
Mark Dell'Acqua
Jerod Denton
Lakshmi Devi
Henrik Dohlman
George Dubyak
Frederick J. Ehler
Michael Freissmuth
Liwu Fu
Yoshiaki Fujii-Kuriyama
Aurelio Galli
Adolfo Garcia-Sainz
Ulrik Gether
Alasdair Gibb
Frank J. Gonzalez
Michael M. Gottesman
Patrick Griffin
Grace Guo
J. Silvio Gutkind
Randy A. Hall
Kasper Hansen
Donald Hilgemann
Miwako Kato Homma
Peter Houghton
Hidenori Ichijo
Hiroshi Itoh
Kenneth A. Jacobson
Andrew Jenkins
Ralf Jockers
Eric F. Johnson
Mathew Jones
Thomas Kash
Marcelo Kazanietz
John Kehrl
Terry Kenakin
Brian K. Kobilka
Evi Kostenis
Rakesh Kukreja
Nevin Lambert
Phillip Lazarus
L.M. Fredrik Leeb-Lundberg
Henry Lester
Lian Li
Sophie Lotersztajn
Angeline Lyon
Ken Mackie
Adriano Marchese
Jeffrey Martens
James O. McNamara
Laurence Miller
Graeme Milligan
Peter Mohler
Richard R. Neubig
Kim A. Neve
Eric Ortlund
Rennolds S. Ostrom
Robert E. Oswald
Jean-Philippe Pin
John J. Reiners, Jr.
Michael B. Robinson
Cheryl Rockwell
Michael A. Rogawski
Bryan L. Roth
Siddhartha Roy
Gunnar Schulte
Zhi Shi
Shivendra V. Singh
Bruno Steiger
Gregory Tall
Andrew Tobin
JoAnn Trejo
Joanne Wang
David J. Waxman
Jurgen Wess
Keith Williams
Wen Xie
Richard D. Ye
Lixia Yue
Michael Zhu

Molecular Pharmacology

molpharm.aspetjournals.org



Molecular Pharmacology publishes findings derived from the application of innovative structural biology, biochemistry, biophysics, physiology, genetics, and molecular biology to basic pharmacological problems that provide mechanistic insights that are broadly important for the fields of pharmacology and toxicology. Relevant topics include:

- Molecular Signaling / Mechanism of Drug Action
- Chemical Biology / Drug Discovery
- Structure of Drug-Receptor Complex
- Systems Analysis of Drug Action
- Drug Transport / Metabolism

Scope:

Molecular Pharmacology welcomes original reports of technically robust and scientifically sound research providing new insights into molecular mechanisms relevant to pharmacology, pharmaceutical sciences, and drug discovery across therapeutic modalities. Examples include studies of drug-receptor interactions, the impact of receptor function on cell or system physiology, receptor-linked intra- or intercellular signaling systems, enzyme or transporter function, drug delivery, drug metabolism, pharmacogenomics, ion channel function, transcriptional mechanisms, molecular mechanisms underlying disease, mechanisms of agonism, antagonism, allosteric modulation, and signaling bias. Work focused on the major receptor types (GPCRs, receptor tyrosine kinases, nuclear receptors, etc.) and ion channels, for example, are encouraged. Manuscripts that identify novel drug targets, approaches to treat disease or protect tissues from damage, mechanisms of action for xenobiotics, or insights into toxicologic mechanisms are also welcome, as are studies that report the development of novel reagents or technologies that are of broad applicability or yield new molecular insights. Reports that include translational studies, relevant to any of the molecular topics mentioned above, are also encouraged. Studies involving molecular or mathematical modeling relevant to drug design or drug action will also be considered if they include new experimental data or test existing experimental data to support the model(s). The journal welcomes minireview articles addressing timely issues in the field of molecular pharmacology.

- Published continuously
- Impact Factor: 3.664 (2019)
- H Index: 186
- Acceptance rate: 58%
- Average time to first decision: 20 days
- Average time to acceptance: 97 days
- Manuscripts published online within 2-3 business days of acceptance and freely accessible to all




facebook.com/molpharmaspetjournal

twitter.com/MolPharmJournal



Drug Metabolism and Disposition

dmd.aspetjournals.org



Drug Metabolism and Disposition (DMD) presents important research in pharmacology and toxicology and is a valuable resource in drug design, drug metabolism, drug transport, expression of drug metabolizing enzymes and transporters, and regulation of drug metabolizing enzyme and transporter gene expression.

Scope:

Drug Metabolism and Disposition will consider for publication manuscripts describing the results of original basic and clinical research that contribute significant and novel information on the metabolism, transport, and disposition of drugs, therapeutic macromolecules, environmental chemicals and in some instances endogenous compounds. Manuscripts that describe mechanistic aspects of drug metabolism and transport as well as those examining mechanisms that affect expression and regulation of drug-metabolizing enzymes and transporters, including genetic variability, are encouraged. Manuscripts concerned with genetic, nutritional, or hormonal factors that influence the biological fate of chemicals are also of interest, as are those that address the toxicologic consequences of xenobiotic metabolism.

Manuscripts describing metabolite identification and/or identification of specific enzymes responsible for particular metabolic pathways, and manuscripts presenting the results of pharmacokinetic/pharmacodynamic studies will be considered only if they have broader impact beyond the compound(s) under study, offer new insights into important existing drugs or toxicants, or address mechanisms underlying xenobiotic disposition and response. Descriptive studies lacking such insights will not be considered for review. Authors should highlight the important aspects of such manuscripts in the cover letter and abstract.

- Published continuously
- Impact Factor: 3.231 (2019)
- H Index: 161
- Acceptance rate: 63%
- Average time to first decision: 19 days
- Average time to acceptance: 80 days
- Manuscripts published online within 2-3 business days of acceptance and freely accessible to all

Editorial Board

Xinxin Ding, *Editor*

Associate Editors:

Wayne L. Backes
Deepak K. Dalvie
Robert S. Foti
Nina Isoherranen
J. Steven Leeder
R. Scott Obach
Mary Paine
David S. Riddick
John D. Schuetz
Aiming Yu

Minireviews Editors:

Yurong Lai
Xiao-bo Zhong

Scientific Advisory Board:

M.W. Anders
Frederick P. Guengerich
James R. Halpert
Magnus Ingelman-Sundberg
Eric F. Johnson
Anthony Y. Lu
Bettie Sue Masters
Edward T. Morgan
Paul R. Ortiz De Montellano

Editorial Board Members:

Lauren Aleksunes
Pieter P.J. Annaert
Upendra Argikar
Thomas Baillie
Huichang Bi
Michael Cameron
Matthew A. Cerny
Eric Chan
Thomas K.H. Chang
Cuiping Chen
Nathan J. Cherrington
Uwe Christians
Raymond Evers
Aleksandra Galetin
Bruno Hagenbuch
Ronald N. Hines
Min Huang
W. Griffith Humphreys
J. Matthew Hutzler
Margaret O. James
Hyunyoung Jeong
Amit S. Kalgutkar
Hiroyuki Kusuvara
Lawrence H. Lash
Chuan Li
Xingrong Liu
Kazuya Maeda
Don Mager
Qingcheng Mao
Jose J. G. Marin
Donald Mercante
Grover P. Miller
Swati Nagar
K. Sandy Pang
Bhagwat Prasad
Brooke M. Rock
Aarti Sawant-Basak
Emily E. Scott
Michael Sinz
Raju Subramanian
Yun K. Tam
Ikumi Tamai
Mitchell E. Taub
Rommel Tirona
Jan Wahlstrom
Joanne Wang
Ronald E. White
Wen Xie
Shinji Yamazaki
Maciej Zamek-Gliszczyński
Su Zeng
Donglu Zhang
Michael Zientek



facebook.com/dmdaspetjournal

twitter.com/DMD_Journal



Editorial Board

Eric L. Barker, *Editor*

Associate Editors:

Stephen P. Alexander
Robert Dantzer
Lynette Daws
Charles France
Michael Gottesman
Jukka Hakkola
Birgitte Holst
Vivian Hook
Paul A. Insel
Yoshihiro Ishikawa
Hyunyoung (Young) Jeong
Habibeh Khoshbouei
Finn Olav Levy
Qiang Ma
Martin Michel
Susan Mooberry
Michael Nader
Eliot Ohlstein
Clive Page
Amin Rostami-Hodjegan
Nancy R. Rusch
John D. Schuetz
Gunnar Schulte
Ulf Simonsen
Rhian M. Touyz
Richard D. Ye

Editorial supervision of
Pharmacological Reviews is
shared jointly with the British
Pharmacological Society and the
Scandinavian pharmacological
societies.

Pharmacological Reviews

pharmrev.aspetjournals.org



Pharmacological Reviews presents important review articles covering the broad spectrum of pharmacological research. Topics covered have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. IUPHAR nomenclature reports are published here.

Scope:

Pharmacological Reviews publishes papers that provide a comprehensive perspective of innovations in pharmacology and experimental therapeutics. High priority will be given to papers that critically examine potential novel therapeutic targets or approaches. Manuscripts should integrate work on basic and cellular pharmacology as well as physiologic aspects germane to the topic. Authors are encouraged to discuss data relevant to the clinical application of the field reviewed.

Papers published in *Pharmacological Reviews* are generally invited by the Editor after consideration of recommendations from the Associate Editors. Others who have an interest in writing for the journal are encouraged to send proposals to the Editor. The proposal should include a detailed outline of the proposed article and a brief curriculum vitae.

Articles in *Pharmacological Reviews* deal mainly with the current status of the subject under review. They are to be written clearly and concisely and should be intelligible to nonspecialists, with definitions of unfamiliar technical terms and explanations of difficult or controversial points included. At the same time, the review is to be sufficiently precise and detailed to command the attention and respect of experts in the field. Selective rather than exhaustive coverage of the literature is requested. Previous reviews of the subject and of related fields should be cited. Authors are asked to be critical of methods, results, and conclusions and to challenge accepted concepts where warranted. Conflicting points of view are to be presented objectively in good perspective. Deficiencies in the field may be pointed out and avenues for further work may be indicated. The usual length ranges between 10 and 30 printed pages, corresponding to about 30 to 90 manuscript pages. Diagrams, tables, and illustrations should be included to bring out new concepts and important relationships.

- Published continuously
- Impact Factor: 17.395 (2019)
- H Index: 210




facebook.com/pharmrevaspetjournal

twitter.com/PharmRevJournal



Pharmacology Research & Perspectives

PharmacolResPerspect.com



Pharmacology Research & Perspectives is the outlet for fundamental and applied pharmacology. An official journal of the American Society for Pharmacology and Experimental Therapeutics and the British Pharmacological Society, this gold open access journal publishes original research, reviews, and perspectives in all areas of preclinical and clinical pharmacology, education, and related research areas including articles that disprove a hypothesis.

Scope:

PR&P is a bi-monthly open access journal that publishes a range of article types, including: original research, reviews, perspectives, commentaries and case studies that address important topics in pharmacology. *PR&P* publishes papers submitted directly to the journal and those referred from supporting journals including ASPET and BPS.

Topics of interest include:

- New pharmacological hypotheses;
- Mechanism of action;
- Drug target identification and preclinical and clinical validation;
- Drug discovery reviews;
- Frontiers in translational medicine; and
- Replication studies.

PR&P is published continuously. The journal is included in a wide array of abstracting and indexing services. All content is immediately open access. *PR&P* is fully compliant with all open access mandates.

Impact Factor: 2.052 (2019)

Editorial Board

Michael F. Jarvis, *Editor-in-Chief*

Jennifer Martin, *Deputy Editor*

Federico Monczor, *Regional Editor for the Americas*

Beáta Sperlágh, *Regional Editor for Europe*

Schuichi Koizumi, *Regional Editor for the Asia-Pacific Region*

Associate Editors:

Nahohiko Anzai
Mark Connor
C. Justin Lee
Dave MacEwan
H. Uri Saragovi

Reviewing Editors:

Leon Aarons
Richard Amison
Chris Bailey
Alakananda Basu
Mary-Ann Bjornsti
Scott Bitner
Stefan Böhm
Robyn Brown
Stefania Ceruti
Ioannis Charalampopoulos
Luigi Calzetta
Ross Corriden
Margaret Cunningham
Brian Enright
Natalia C. Fernández
Ryoichi Fujiwara
Natasha Grimsey
Michelle Halls
Christian Höcht
Dana Hutchinson
Peter Jackson
Jianguo Ji
Hiroshi Katsuki
Jee Hyan Kim
Attila Köfalvi
Masuo Kondoh
Ryuta Koyama
Anurag Kuhad
Hiroyuki Kusuhara
Derek Lang
John Lazo
Chih-Hung Lee
Jian-Hui Liang
Anastassios Lymperopoulos
Graham A. Mackay
Patricia McGettigan
Daniel Morgan
Masabumi Minami
Motohiro Nishida
Akira Nishiyama
Terence Pang
Jeff Paul
Claudia Pérez Leirós
Erika Pinter
Liz Rosethorne
Ana Sahores
Toshiyuki Sasaguri
Kaoru Sato
Daniel Scott
Elizabeth Sharlow
Hisashi Shirakawa
Chris Southan
Kyoungso Suk
Zaijie Wang

Social Media Coordinator
Stephanie Davis

Editorial Office
Alice Kallaway, Associate
Managing Editor



facebook.com/PRandPJournal

twitter.com/PRandP_Journal



Journal Benefits for ASPET Members

ASPET members have access to a variety of member benefits. Join today at www.aspet.org/membership



Member Benefits Include:

- Reduced page charges to publish in ASPET journals
- No manuscript submission fee
- Full-text access to all ASPET journals, including back issues to Volume 1, Issue 1

Access your journal subscriptions:

ASPET membership includes online access to the Society's journals.

To activate your member subscription:

- Step 1:** Visit www.aspet.org/activate-subscription.
- Step 2:** Enter your ASPET member number and click "Submit".
- Step 3:** Create a user name and password for your online subscription.
- Step 4:** Enjoy your full access to ASPET's journals.

If you have an access problem with your ASPET journals, please send a message to subscriptions@aspet.org. Messages are monitored by several ASPET staff members to provide rapid customer service.

Not a member but would like access to ASPET Journals?

Ask your librarian to subscribe!

Learn more at <https://bit.ly/2P5U7BR>